Problems involved in the induction of protective immunity against cholera are mostly related to the noninvasive nature of the pathogen (17) . Throughout the course of infection, Vibrio cholerae is confined to the intestinal lumen and mucosal surface, where it is partially isolated from the full array of host defense mechanisms that would normally be directed against an invasive organism. Vibrios produce a well-characterized enterotoxin, which binds to an epithelial ganglioside receptor (7, 20) and causes the fluid outpourings characteristic of cholera. It is reasonable to assume that a humoral response directed against either the bacteria or toxin confers protection only ifspecific antibody is present within the intestinal lumen or at the epithelial surface of the host's small intestine.
In cholera-endemic areas, a lower rate of reinfection and a decrease in incidence of disease has been correlated with increasing age (26) .
This indicates that a significant degree of specific immune protection is acquired through exposure to V. cholerae antigens. Further evidence from volunteer studies (5, 28) shows that convalescents from induced cholera were resistant to homologous challenge for up to 12 months. Nevertheless, conventional cholera vaccines consisting of parenterally administered killed cells have proven relatively ineffective in field trials (1, 8, 26, 27) . There is a protection rate of about 40 to 60% during the first 2 months, but this falls to between 10 and 20% after 6 months. The level of protection afforded by killed-cell vaccines seems to correlate with a rise in the titer of serum vibriocidal antibody (25) (26) (27) . The inadequacy of these vaccines is possibly related to their inability to elicit substantial coproantibody. Freter and Gangarosa (14, 15) have advocated the use of orally administered killed vibrios to elicit and maintain gut immunity. However, prolonged protection by this route has not been demonstrated, and the large quantities of antigen that must be ingested render the feasibility of this technique unlikely.
Antitoxic as well as antibacterial antibodies are produced during the immune response to cholera infection in humans (4, 6, 30) . Although there is no direct evidence that antitoxin plays a role in recovery from the disease, the prophylactic potential of antitoxic immunity is obvious. Finkelstein and Hollingsworth (12, 13) induced antitoxic immunity in rats and rabbits with subcutaneous injections of a formalinized toxoid vaccine. Although somewhat variable, this immunity was protective against both homologous and heterologous challenge. Northrup and Chisari (29) , in subsequent studies with monkeys, found that the formalinized toxoid vaccine reverted to toxin in vivo and caused a severe localized reaction to subcutaneous injection. Similar reactions were experienced by human volunteers inoculated with 25 jig of toxoid vaccine, which is less than the amount believed necessary for the induction of effective immunity (32) . The probability of harmful side effects due to toxoid reversion is apparently reduced by oral immunization (16) . However, antitoxic immunity by this route in mice required up to 100 times more antigen to attain a level of protection comparable to that induced parenterally. Rappaport et al. (31) produced a stable toxoid vaccine by treating purified toxin with glutaraldehyde. The product was reported to be somewhat less immunogenic than formalinized toxoid, but its antigenicity was enhanced by combining the toxoid with an alum adjuvant. However, a recent report from field trials in Bangladesh with the glutaraldehyde-treated toxoid vaccine indicates disappointing results (G. T. Curlin, J. Chakravorty, K. M. A. Aziz, R. J. Levine, and W. F. Verwey, in Proceedings of the 14th Joint Conference, U.S.-Japan Cooperative Medical Science Program, Cholera Panel, in press). The risk of cholera infection in an endemic area was found to be more closely related to such factors as the source of domestic water for bathing and drinking than to the serological status of toxoidimmunized individuals. Experiments presented here compare the level of protective immunity afforded adult rabbits by the toxoid vaccine versus that conferred by a motility-related immunogen described below.
Previous studies from this laboratory have demonstrated the importance of motility as a virulence factor in cholera (10, 18, 35) . Experiments with the infant mouse model (18) and in rabbit ligated ileal loops (35) strongly suggest that an intimate association of vibrios with the intestinal mucosa is necessary for efficient toxin delivery. Nonmotile but fully toxinogenic and prototrophic mutant derivatives of motile, highly virulent parental strains showed a greatly reduced ability to associate with the intestinal mucosa and to produce disease symptoms. Since motility (or some factor related to the expresssion of motility [23] ) is essential for the induction of cholera, Eubanks et al. (11) Toxoid for subcutaneous injection was rehydrated to a concentration of 200 ,ug/ml with a protamine sulfatealuminum chloride diluent containing 3.75 mg of aluminum chloride per ml, 0.5 mg of protamine sulfate per ml, and 0.05 mg of thimerosal per ml. This alumprecipitated toxoid solution was administered in 0.5-ml doses.
CF was prepared from the highly motile strain CA401 by a modification of the method of Eubanks et al. (11) . Cells from an 8-h brain heart infusion agar slant were suspended in PBSG and inoculated into a 1-liter flask containing 200 ml of brain heart infusion broth. The broth culture was incubated at 37°C on a rotary shaker (150 rpm) for 14 to 18 h, and these cells (early stationary phase) were inoculated into a 20-liter carboy containing 10 liters of brain heart infusion broth. This large culture was incubated at 37°C with aeration for 4 h, after which the cells were harvested by centrifugation (6,000 x g) and resuspended in 180 ml of 1 Preparation of ligated ileal loops. Heal loops were prepared by a modification of the method of De and Chatterje (9) . Rabbits were fasted for 48 h to allow elimination of fecal pellets. One-half milliliter of a vibrio suspension, appropriately diluted in PBSG, was injected into segments of the ligated ileum, each approximately 6 to 9 cm in length and each separated by an uninoculated segment of about 2 cm. Control loops received 0.5 ml of PBSG or 0.5 ,ug of cholera toxin in 0.5 ml of diluent. After 18 h (or at shorter intervals, if required), the rabbits were sacrificed and the ileum was excised. Loops were carefully measured, and the ratio of the volume of fluid accumulated (in milliliters) to the length of the segment (in centimeters) was calculated and expressed as the fluid accumulation (FA) ratio.
Adsorption of 3S-labeled vibrios. Vibrios were labeled by the procedure of Baselski and Parker (2).
35S-abeled cells were injected into the ligated loops of normal and CF-immune rabbits and assayed after 3 h of incubation, as described previously (35) . The number of counts associated with tissue sections was compared with the number remaining unattached in the gut fluid. From 70 to 98% of the total injected counts were recoverable by this technique.
Absorption of anti-CF antiserum with aflagellated cells of V. cholerae. Complement-inactivated (560C for 30 min) antisera from rabbits immunized with CF were pooled and sterilized by passing through a 0.45-,um filter. Preimmune sera collected from the same rabbits prior to immunization were used for control. One-half of each pool was absorbed with aflagellated cells by the procedure below, and the other half was reserved for comparison.
Approximately 1010 Formalin-killed cells of the aflagellated mutant strain CA401 M-6 were washed three times with sterile saline and suspended in 5 ml of immune serum. After incubation at 370C for 30 min, the cells were pelleted by centrifugation. The serum was decanted and added to an equal volume of washed, Formalin-killed cells. Again after incubation at 370C for 30 min, the cells were removed by centrifugation.
The remaining cells were removed by passing the serum through a 0.45-am filter.
Serum titers. Anti-O (somatic) and anti-H (flagellar) titers of serum from immunized rabbits were determined by the quantitative tube agglutination test. Serial dilutions of complement-inactivated serum were made in sterile saline (0.5 ml per tube). Cells of V. cholerae CA401 were grown at 370C for 14 h on Trypticase soy agar slants. Vibrios to be used for anti-0 determination were harvested in normal saline and killed by heating for 30 min in a boiling water bath. Cells for H-agglutination were killed by suspending in normal saline containing 1% Formalin for 30 to 60 min.
The turbidity of these suspensions was adjusted to match a 100 Klett unit standard, and 0. Association of vibrios with the ileal mucosa of normal and immune rabbits. Guentzel et al. (19) used fluorescent antibodies to demonstrate the inability of motile, highly virulent vibrios to successfully associate with the leal mucosa of infant mice passively immunized to CF. The results were similar to those obtained with nonmotile mutant strains of V. cholerae in normal infant mice (19) and, more recently, with nonmotile mutant strains in nonimmune adult rabbits (35) . The results presented in Fig. 2 extend this comparison to the association of motile, virulent, 3S-labeled bacteria with the mucosa ofnormal and CF-immune adult rabbits. About 50% of the total recoverable counts were associated with ileal sections in normal rabbits. This level of tissue association decreased to between 11 and 23% in immune animals. The difference is statistically significant with the El Tor strains (8233 and HK-1) as well as classical strains of both serotypes (P < 0.01).
Comparison of the efficacy of CF, CV, and cholera toxoid. The effectiveness of CF as an unogen was compared to those of a commonly employed CV and cholera toxoid. Rabbits were immunized, as described above, with subcutaneous injections of CV diluted to a protein concentration 10 Similar results were obtained when CV-immunized rabbits were challenged with CA411. Fig. 4 , which summarizes the fluid response to two challenge doses (106 and 108 CFU) of the classical Ogawa strain, shows that FA ratios in CV-immunized rabbits were at least as great as in control rabbits. Heterologous protection in CF-immunized rabbits is evidenced by significantly lower FA ratios at both challenge doses.
Mean FA ratios for two challenge doses were slightly lower for CA411 than CA401 (Fig. 3) in toxoid-immunized rabbits. However, maximal FA ratios in control animals were also lower for the Inaba strain, so actual protection was about the same. The FA ratio in toxoid-immunized rabbits challenged with 106 CFU was approximately equal to the FA ratio in CF-immunized rabbits challenged with 108 CFU. This indicates that, on a dose basis, CF protection by this immunization schedule was about 100 times more effective than toxoid immunity.
Passive protection of ileal loops in normal rabbits with anti-CF antiserum. Normal rabbits were passively immunized with various dilutions of complement-inactivated anti-CF antiserum introduced into ligated ileal loops along with 108 virulent CA401 cells. The upper portion of Evidence that passive protection might be due to anti-flagellar antibody was obtained by absorbing the serum twice with an aflagellated derivative of CA401, as described in Materials and Methods. The data presented in the lower part of Fig. 5 show that no appreciable loss in passive immunity resulted. The anti-O titer of the serum was reduced below a detectable level by absorption, while the ability to reduce fluid but not lipopolysaccharide), and the rabbits were immunized with this material as before. The FA response to challenge with homologous (CA401) and heterologous (CA411) strains in rabbits immunized with heat-treated CF was not significantly different from that of unimmunized controls. Data from rabbits immunized with unheated CF are included for comparison.
Role of IgA and IgG in intestinal anti-CF immunity. Goat anti-rabbit IgA and goat antirabbit IgG were introduced into the ligated ileal loops of CF-immune rabbits along with virulent CA401 cells as described above. Initial results indicated optimum reversal of immune protection with goat anti-rabbit serum at a dilution of about 10-. There may have been a slight prozone effect at the lower (101) dilution, since reversal of protection was not as evident at this dilution of anti-immunoglobulin serum. Data obtained at the optimal dilution are presented graphically in Fig. 7 accumulation was not affected.
Immunogenicity of the heat-treated CF vaccine. Evidence that the immunogenic component of the CF preparation was not contaminating lipopolysaccharide is indicated by the results presented in Fig. 6 . In this experiment, the CF vaccine was heated at 100'C for 15 Fig. 1 ) and excellent passive protection (Fig. 5) . CV given by the same route but with 10 times as much protein (and even more lipopolysaccharide) did not induce significant protection (Fig. 3 and 4) . The glutaraldehyde-treated Wyeth toxoid gave some protection at a dose of 200 ,ug but less protection than that provided by the same amount of CF vaccine.
There is no definitive explanation for the high degree of active protection afforded by CF immunity. Bacterial motility is probably inhibited, though this would be difficult to demonstrate in vivo. The in vitro inhibition of motility by specific antiserum was used by Benenson et al. (3) to identify vibrios in stool samples of patients with acute diarrhea. Williams and his co-workers (34) used motility inhibition as a method for determining titers of immune serum raised against whole cells or purified somatic antigen. Motility inhibition titers of anti-CF antiserum (1:1,100) were not significantly higher than those reported for antibacterial antisera (34) .
The association of motile, virulent vibrios with the leal mucosa was significantly reduced in rabbits immunized with CF (Fig. 2) . These results are similar to those reported by Guentzel et al. (19) in passively immunized mice and in nonimmune animals challenged with nonmotile vibrios (19, 35) . Thus, the reduced association of vibrios with the ileal mocosa of immune animals might result from the inhibition of bacterial motility, but other data from normal and immune animals challenged with motile and nonmotile vibrios suggest that anti-CF immunity might involve something other than, or in addition to, motility inhibition. Nonmotile vibrios produce maximal FA ratios in normal rabbits at a challenge inoculum of 108 CFU of toxinogenic cells. This challenge dose with nonmotile vibrios resulted in maximal fluid accumulation, whereas the data in Fig. 1 and 3 show that a significant reduction in fluid accumulation occurred after challenge with 108 CFU of motile strain CA401 in CF-immune animals.
The decrease in attachment of radiolabeled vibrios to the mucosa of rabbits vaccinated with CF is about 60% (Fig. 2) , whereas the increase in challenge dose required for maximum FA in vaccinated animals was 100-to 1,000-fold (Fig.  1 ). The two changes should not necessarily be expected to correlate, since the timing was different (3 h for attachment and 18 h for fluid accumulation) and, more importantly, attachment probably depends on physical phenomena while fluid loss depends on the catalytic activity of toxin.
The basis for CF immunity cannot be attributed to contaminating enterotoxin in the preparations, since the immunized rabbits produced maximal FA in loops challenged with as little as 0.2 ug of cholera toxin. Moreover, assays for toxin by the morphological change induced in Chinese hamster ovary cells indicated the presence of less than 1 ng/mg of protein in the CF preparations or less than 200 pg per immunizing dose (unpublished data of D. S. Schneider and R. J. Yancey). It is possible, however, that the CF vaccine contains vibrio surface components similar to adhesive K88 antigen of Escherichia coli (24) . Cholera vibrios may possess a similar antigen (22, 23) , which contaminates the CF vaccine and can then induce a response that simultaneously neutralizes the adhesive factor and impairs bacterial motility. This assumption cannot be confirmed, however, until the specific antigenic components of CF are determined.
High vibriocidal titers might account for the observed level of protection beyond that expected by motility inhibition alone. Vibriocidal titers of serum from CF-immune rabbits were found to be very high, but the data (not shown) varied greatly depending upon the assay. It would be difficult to correlate these titers with vibriocidal activity within the small intestine. The nature of the coproantibody response to CF immunization, as revealed by the use of goat anti-rabbit IgA and goat anti-rabbit IgG, indicated that both classes of immunoglobulins are required for effective protection at the site of infection (Fig. 7) . It was not determined whether the IgG was serum derived or a normal component of intestinal immunity.
Holmgren et al. (21) recently reviewed the pathogenic mechanisms involved in cholera and the vaccines currently available. They recommended the use of an improved vaccine com-prised of cholera toxin and lipopolysaccharide antigens. With this combined vaccine, they were able to demonstrate a 100-fold increase in immune protection of adult rabbits. The results presented here demonstrate that a similar level of protection in adult rabbits is attained by immunization with the subcellular CF vaccine alone. A combined CF-toxoid vaccine might prove to be optimal for human prophylaxis against cholera.
